🇺🇸 FDA
Patent

US 11524017

Method of using substrates of AKR1B1/AKR1B10 as anti-cancer drugs

granted A61KA61K31/11A61K31/121

Quick answer

US patent 11524017 (Method of using substrates of AKR1B1/AKR1B10 as anti-cancer drugs) held by Beijing Normal University Hong Kong Baptist University United International College expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Beijing Normal University Hong Kong Baptist University United International College
Grant date
Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/11, A61K31/121, A61K31/19, A61K31/191